Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

101.34USD
17 Aug 2018
Change (% chg)

$-0.40 (-0.39%)
Prev Close
$101.74
Open
$100.82
Day's High
$101.69
Day's Low
$100.72
Volume
26,548
Avg. Vol
31,824
52-wk High
$121.08
52-wk Low
$84.15

Chart for

About

No overview information found for .

Overall

No Ratios Available.

Financials

  GLPG.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -- -- --
ROI: -- 2.89 12.63
ROE: -- 1.65 14.82

BRIEF-Galapagos NV reports H1 Group Revenues Of €101.9 Million

* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION

Aug 02 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Jul 19 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Jul 19 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

Jun 21 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

May 01 2018

BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018

* REG-GALAPAGOS PRESENTS STRONG DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODEL OF OSTEOARTHRITIS WITH GLPG1972 AT OARSI 2018

Apr 27 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

Apr 25 2018

BRIEF-Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73

* GALAPAGOS EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018

Apr 25 2018

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

Apr 19 2018

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

Apr 12 2018

Earnings vs. Estimates